0000883984-21-000014 | 10-Q | XBRL Viewer

TOTAL CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES

11,693

14,687

^[1]

435,942

410,784

^[1]

Accounts receivable, net of allowance for doubtful accounts of $21,782 at March 31, 2021 and $21,490 at December 31, 2020

120,365

124,093

^[1]

Inventories

300,086

314,928

^[1]

Prepaid income taxes

31,480

29,480

^[1]

Prepaid expenses and other current assets

40,309

41,492

^[1]

TOTAL CURRENT ASSETS

928,182

920,777

^[1]

PROPERTY AND EQUIPMENT, net

459,072

466,628

^[1]

Operating Lease, Right-of-Use Asset

45,259

46,571

^[1]

Deferred Income Tax Assets

18,834

12,974

GOODWILL

32,952

33,001

^[1]

INTANGIBLE ASSETS, net

193,074

197,231

^[1]

29,115

31,034

OTHER ASSETS

58,742

55,475

^[1]

TOTAL ASSETS

1,765,230

1,763,691

^[1]

CURRENT LIABILITIES:

Accounts payable

73,049

71,864

^[1]

Accrued liabilities

79,056

97,021

^[1]

Income tax liability

1,457

303

^[1]

Contingent earn-out liability

26,300

TOTAL CURRENT LIABILITIES

179,862

195,488

^[1]

Other long-term liabilities

46,110

47,835

DEFERRED INCOME TAXES

1,663

^[1]

INCOME TAX LIABILITY

16,827

16,440

^[1]

COMMITMENTS AND CONTINGENCIES

^[1]

STOCKHOLDERS' EQUITY:

Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none

^[1]

Common stock, $0.10 par value - Authorized-80,000 shares; Issued 21,219 shares at March 31, 2021 and 21,058 shares at December 31, 2020 and outstanding 21,192 shares at March 31, 2021 and 21,058 shares at December 31, 2020

2,122

2,106

^[1]

Additional paid-in capital

701,586

693,068

^[1]

Treasury Stock, at cost (26,785 and 209 shares, respectively)

(5,410)

(39)

^[1]

Retained earnings

832,383

808,652

^[1]

Accumulated other comprehensive loss

(9,913)

(1,522)

^[1]

TOTAL STOCKHOLDERS' EQUITY

1,520,768

1,502,265

^[1]

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

$ 1,765,230

$ 1,763,691

^[1]

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 21,782	$ 21,490
Convertible preferred stock, par value	$ 1.00
Convertible preferred stock, authorized shares	500,000
Convertible preferred stock, issued shares	0	0
Convertible preferred stock, outstanding shares	0	0
Common stock, par value	$ 0.10
Common stock, shares authorized	80,000,000
Common stock, shares issued	21,219,000	21,058,000
Common stock, shares outstanding	21,192,000	21,058,000
Treasury Stock, Shares	26,785	209

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
REVENUES:
Revenue from Contract with Customer, Excluding Assessed Tax	$ 318,046	$ 328,607
Cost of goods sold	205,366	207,192
Gross Profit	112,680	121,415
OPERATING EXPENSES:
Selling, general and administrative	72,391	72,305
Research and development	10,709	10,746
Restructuring, strategic transaction and integration	2,883	12,307
Change in fair value of contingent earn-out	0	0
contract settlement	127	0
TOTAL OPERATING EXPENSES	86,110	95,358
INCOME FROM OPERATIONS	26,570	26,057
Interest Expense	(161)	(196)
OTHER INCOME (EXPENSE), net	683	(5,480)
INCOME BEFORE INCOME TAXES	27,092	20,381
PROVISION FOR INCOME TAXES	(3,361)	(3,547)
NET INCOME	$ 23,731	$ 16,834
NET INCOME PER SHARE
Basic (in dollars per share)	$ 1.12	$ 0.81
Diluted (in dollars per share)	$ 1.09	$ 0.78
WEIGHTED AVERAGE NUMBER OF SHARES
Basic (in shares)	21,149	20,780
Diluted (in shares)	21,695	21,507

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net Income	$ 23,731	$ 16,834
Other comprehensive income (loss), net of tax
Cash flow hedge adjustments, net of taxes of $356 and $116 for the three and months ended June 30, 2020 and 2019, respectively, and ($577) and $322 for the six months ended June 30, 2020 and 2019, respectively	(945)	(2,952)
Foreign currency translation adjustment, net of taxes of $0 for all periods	(7,458)	(10,477)
Other Comprehensive Income (Loss), Other Adjustments, after Tax	12	(81)
Other comprehensive income (loss), net of taxes	(8,391)	(13,510)
Comprehensive Income	$ 15,340	$ 3,324

Amount after tax and reclassification adjustments of other comprehensive income (loss).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

CASH FLOWS FROM OPERATING ACTIVITIES:

Condensed Consolidated Statements of Comprehensive Income (Paranthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax	$ 298	$ 932
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	0	0
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax	$ 0	$ 0

Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock Shares [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Common stock, shares outstanding at Dec. 31, 2019		20,742,000
Stockholders' Equity Attributable to Parent at Dec. 31, 2019	$ 1,377,244		$ 2,074	$ 668,947	$ (157)	$ 721,782	$ (15,402)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, New Issues		155,000
Stock Issued During Period, Value, New Issues	$ 560		9		10,758
Adjustments to Additional Paid in Capital, Other				(10,207)
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation	(63,511)	(64,000)
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	$ (12,174)				(12,174)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	6,939			6,939
Other Comprehensive (Loss) Income, Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(13,510)
Net Income Attributable to Parent	16,834					16,834
Stockholders' Equity Attributable to Parent at Mar. 31, 2020	1,375,893		2,083	665,679	(1,573)	738,616	(28,912)
Common stock, shares outstanding at Mar. 31, 2020		20,833,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	$ (13,510)						(13,510)
Common stock, shares outstanding at Dec. 31, 2020	21,058,000	21,058,000
Stockholders' Equity Attributable to Parent at Dec. 31, 2020	$ 1,502,265		2,106	693,068	(39)	808,652	(1,522)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock Issued During Period, Shares, New Issues		198,000
Stock Issued During Period, Value, New Issues	$ 4,864		16		2,352
Adjustments to Additional Paid in Capital, Other				2,496
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation	(37,423)	(37,000)
Share-based Payment Arrangement, Decrease for Tax Withholding Obligation	$ (7,723)				(7,723)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	6,022			6,022
Other Comprehensive (Loss) Income, Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(8,391)
Net Income Attributable to Parent	23,731					23,731
Stockholders' Equity Attributable to Parent at Mar. 31, 2021	$ 1,520,768		$ 2,122	$ 701,586	$ (5,410)	$ 832,383	(9,913)
Common stock, shares outstanding at Mar. 31, 2021	21,192,000	21,219,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other Comprehensive income (loss), net of Tax	$ (8,391)						$ (8,391)

Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2021

Mar. 31, 2020

Net Income

$ 23,731

$ 16,834

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

22,155

20,957

Operatingleaserightofuseassetamortization

2,372

2,305

Provision for doubtful accounts

Provision for warranty and returns

209

(821)

Stock compensation

6,022

6,939

Loss on disposal of property and equipment

659

562

Bond premium amortization

168

Debt Issuance Costs amortization

Change in fair value of contingent earn-out

Inventory Recall Expense

2,626

Sparepartsusage

2,825

4,900

Other Noncash Income (Expense)

(1,287)

876

Cash provided by (used in) changes in operating assets and liabilities

Accounts receivable

1,506

899

Inventories

13,208

19,372

Prepaid expenses and other assets

(742)

2,634

Increase (Decrease) in Other Operating Assets

(3,463)

(6,402)

Accounts payable

2,411

(35,063)

Accrued liabilities

(19,965)

465

Income taxes, including excess tax benefits and deferred income taxes

1,439

2,325

Net cash provided by operating activities

51,320

39,519

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and equipment

(14,028)

(25,463)

Proceeds from sale of asset

131

Intangible assets additions

(1,874)

(1,958)

Purchases of investment securities

(10,034)

(7,082)

Proceeds from sale of investment securities

7,000

10,900

Net cash used in investing activities

(18,881)

(23,472)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from Lines of Credit

150,000

Proceeds from exercise of stock options

4,864

560

Finance Lease, Principal Payments

(141)

Payment, Tax Withholding, Share-based Payment Arrangement

7,723

12,174

Net cash (used in) provided by financing activities

(3,000)

138,386

Effect of exchange rate changes on cash

(1,287)

(3,546)

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect

28,152

150,887

CASH AND CASH EQUIVALENTS, beginning of period

396,097

^[1]

268,670

CASH AND CASH EQUIVALENTS, end of period

424,249

419,557

NON-CASH INVESTING ACTIVITIES

Capital Expenditures Incurred but Not yet Paid

$ 1,068

$ 7,112

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Basis of Presentation:	3 Months Ended
Basis of Presentation:	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S.") and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments, consisting of only normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the consolidated results for the interim periods presented. Results for the interim period are not necessarily indicative of results for the full year. Certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report on Form 10-K of ICU Medical, Inc., ("ICU") a Delaware corporation, filed with the SEC for the year ended December 31, 2020. We are engaged in the development, manufacturing and sale of innovative medical products used in vascular therapy and critical care applications. We sell the majority of our products through our direct sales force and through independent distributors throughout the U.S. and internationally. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers. All subsidiaries are wholly owned and are included in the condensed consolidated financial statements. All intercompany balances and transactions have been eliminated.

New Accounting Pronouncements:	3 Months Ended
New Accounting Pronouncements:	Mar. 31, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	New Accounting PronouncementsRecently Issued Accounting Standards In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update provide optional guidance for a limited period of time to ease the potential burden for reference rate reform on financial reporting. Due to concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The amendments in this update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued as a result of reference rate reform. Optional expedients may be applied to contracts that are modified as a result of the reference rate reform. Modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. Modifications of contracts within the scope of ASC 842, Leases, should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate (incremental borrowing rate). Exceptions to Topic 815, Derivatives and Hedging, results in not having a dedesignation of a hedging relationship if certain criteria are met. The amendments in this ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The impact of this ASU on our contracts has not been material.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recently Issued Accounting Standards In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this update provide optional guidance for a limited period of time to ease the potential burden for reference rate reform on financial reporting. Due to concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate ("LIBOR"), regulators around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction based and less susceptible to manipulation. The amendments in this update apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued as a result of reference rate reform. Optional expedients may be applied to contracts that are modified as a result of the reference rate reform. Modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate. Modifications of contracts within the scope of ASC 842, Leases, should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate (incremental borrowing rate). Exceptions to Topic 815, Derivatives and Hedging, results in not having a dedesignation of a hedging relationship if certain criteria are met. The amendments in this ASU are effective for all entities as of March 12, 2020 through December 31, 2022. The impact of this ASU on our contracts has not been material.

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)

Restructuring and Related Activities [Abstract]

Restructuring, Strategic Transaction and Integration (Notes)

3 Months Ended

Mar. 31, 2021

Restructuring and Related Activities Disclosure

Restructuring, Strategic Transaction and Integration

Restructuring, strategic transaction and integration expenses were $2.9 million and $12.3 million for the three months ended March 31, 2021, and 2020 respectively.

Restructuring

During the three months ended March 31, 2021 and 2020, restructuring charges were $0.0 million and $7.2 million, respectively. Restructuring charges for the three months ended March 31, 2020 were primarily related to severance and costs related to office and other facility closures. Restructuring charges are included in the above restructuring, strategic transaction and integration expenses in our condensed consolidated statement of operations.

The following table summarizes the details of changes in our restructuring-related accrual for the period ended March 31, 2021 (in thousands):


	Accrued Balance January 1, 2021		Charges Incurred		Payments		Currency Translation		Accrued Balance March 31, 2021
Severance pay and benefits	$	1,858	$	43	$	(435)	$	12	$	1,478

Facility closure expenses	1,563		—		—		17		1,580
	$	3,421	$	43	$	(435)	$	29	$	3,058

Strategic transaction and integration expenses

We incurred and expensed $2.9 million and $5.1 million in strategic transaction and integration expenses during the three months ended March 31, 2021 and 2020, respectively, which are included in restructuring, strategic transaction and integration expenses in our condensed consolidated statement of operations. The strategic transaction and integration expenses during the three months ended March 31, 2021 were primarily related to integration costs associated with acquisitions, the Hospira Infusion Systems ("HIS") earn-out dispute with Pfizer and one-time costs incurred to comply with regulatory initiatives. The strategic transaction and integration expenses during the three months ended March 31, 2020 were primarily related to the integration of the HIS business acquired in 2017 from Pfizer, which included the migration of IT systems at our Austin facility.

Revenue (Notes)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

Revenue

Our primary product lines are Infusion Consumables, Infusion Systems, IV Solutions and Critical Care. The vast majority of our sales of these products are made on a stand-alone basis to hospitals and distributors. Revenue is typically recognized upon transfer of control of the products, which we deem to be at point of shipment. However, for purposes of revenue recognition for our software licenses and renewals, we consider the control of these products to be transferred to a customer at a certain point in time; therefore, we recognize revenue at the start of the applicable license term.

Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to our distribution customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time and our historical experience with each customer to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end-customers at prices determined under a contract between us and the end-customer. Chargebacks are the difference between the prices we charge our distribution customers and the contracted prices we have with the end customer which are processed as credits to our distribution customers. In estimating the expected value of chargeback amounts in order to determine the transaction price, we use information available at the time, including our historical experience.

We also warranty products against defects and have a policy permitting the return of defective products, for which we accrue and expense at the time of sale using information available at that time and our historical experience. We also provide for extended service-type warranties, which we consider to be separate performance obligations. We allocate a portion of the transaction price to the extended service-type warranty based on its estimated relative selling price, and recognize revenue over the period the warranty service is provided. Our revenues are recorded at the net sales price, which includes an estimate for variable consideration related to rebates, chargebacks and product returns.

Revenue disaggregated

The following table represents our revenues disaggregated by geography (in thousands):


	For the three months ended March 31,
Geography	2021		2020
Europe, the Middle East and Africa	$	34,800	$	37,928



Other Foreign	55,895		60,521
Total Foreign	90,695		98,449
United States	227,351		230,158
Total Revenues	$	318,046	$	328,607

The following table represents our revenues disaggregated by product (in thousands):


	For the three months ended March 31,
Product line	2021		2020
Infusion Consumables	$	126,370	$	123,507
Infusion Systems	84,334		88,380
IV Solutions	94,176		104,291
Critical Care	13,166		12,429

Total Revenues	$	318,046	$	328,607

Contract balances

The following table presents our changes in the contract balances for the three months ended March 31, 2021 and 2020 (in thousands):


	Contract Liabilities
Beginning balance, January 1, 2021	$	(6,430)
Equipment revenue recognized	461
Equipment revenue deferred due to implementation	(2,921)
Software revenue recognized	1,796
Software revenue deferred due to implementation	(1,794)
Ending balance, March 31, 2021	$	(8,888)

Beginning balance, January 1, 2020	$	(4,855)
Equipment revenue recognized	1,802
Equipment revenue deferred due to implementation	(3,990)
Software revenue recognized	1,235
Software revenue deferred due to implementation	(2,664)
Ending balance, March 31, 2020	$	(8,472)

As of March 31, 2021, revenue from remaining performance obligations related to implementation of software and equipment is $7.3 million. We expect to recognize substantially all of this revenue within the next three to six months dependent on implementation restrictions due to the novel coronavirus and its variants ("COVID-19"). Revenue from remaining performance obligations related to annual software licenses is $1.5 million. We expect to recognize substantially all of this revenue over the next twelve months.

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Lessee, Operating Leases [Text Block]

Leases (Notes)

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Leases

We determine if an arrangement is a lease at inception. Our operating lease assets are separately stated in operating lease right-of-use ("ROU") assets and our financing lease assets are included in other assets on our condensed consolidated balance sheets. Our lease liabilities are included in accrued liabilities, and other long-term liabilities on our condensed consolidated balance sheets. We have elected not to recognize an ROU asset and lease liability for leases with terms of twelve months or less.

Lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Most of our leases do not provide an implicit rate, therefore we use our incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term based on the information available at commencement date. Our lease ROU assets exclude lease incentives and initial direct costs incurred. Our lease terms include options to extend when it is reasonably certain that we will exercise that option. All of our leases have

stated lease payments, which may include fixed rental increases. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

Our leases are for corporate, research and development and sales and support offices, a distribution facility, device service centers and certain equipment. Our leases have original lease terms of one year to fifteen years, some of which include options to extend the leases for up to an additional five years. For all of our leases, we do not include optional periods of extension in our current lease terms for the exercise of options to extend is not reasonably certain.

The following table presents the components of our lease cost (in thousands):


	For the three months ended March 31
	2021		2020
Operating lease cost	$	2,835	$	2,791

Finance lease cost - interest	31		29

Finance lease cost - amortization of ROU asset	151		—

Short-term lease cost	3		54



Total lease cost	$	3,020	$	2,874

Interest expense on our finance leases is included in other income (expense), net in our condensed consolidated statement of operations. The amortization of the operating and finance ROU asset is included in selling, general and administrative expenses in our condensed consolidated statement of operations.

The following table presents the supplemental cash flow information related to our leases (in thousands):


	For the three months ended March 31,
	2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,821	$	2,457
Operating cash flows from finance leases	$	31	$	29

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	1,095	$	19,094
Finance leases	$	184	$	800

The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):


	As of March 31, 2021			As of December 31, 2020
Operating leases
Operating lease right-of-use assets	$	45,259		$	46,571

Accrued liabilities	$	8,872		$	8,740
Other long-term liabilities	39,588			41,019
Total operating lease liabilities	$	48,460		$	49,759

Weighted Average Remaining Lease Term
Operating leases	6.5 years			6.7 years

Weighted Average Discount Rate
Operating leases	5.00		%	5.02		%

The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):


	As of March 31, 2021			As of December 31, 2020
Financing leases
Financing lease right-of-use assets	$	2,877		$	2,915

Accrued liabilities	$	583		$	554
Other long-term liabilities	2,330			2,388
Total financing lease liabilities	$	2,913		$	2,942

Weighted Average Remaining Lease Term
Financing leases	6.2 years			6.4 years

Weighted Average Discount Rate
Financing leases	4.27		%	4.27		%

As of March 31, 2021, the maturities of our operating and financing lease liabilities for each of the next five years is approximately (in thousands):


	Operating Leases		Finance Leases
Remainder of 2021	$	8,352	$	520
2022	10,316		693
2023	9,120		693
2024	8,317		379
2025	5,008		211
2026	4,733		189
Thereafter	10,602		614
Total Lease Payments	56,448		3,299
Less imputed interest	(7,988)		(386)
Total	$	48,460	$	2,913

Net Income Per Share:

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Net Income Per Share [Text Block]

Net Income Per Share

Basic earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding during the period plus dilutive securities. Dilutive securities include outstanding common stock options and unvested restricted stock units, less the number of shares that could have been purchased with the proceeds from the exercise of the options, using the treasury stock method. Options and restricted stock units that are anti-dilutive are not included in the treasury stock method calculation. There were 12,080 and 15,333 anti-dilutive securities for the three months ended March 31, 2021 and 2020, respectively.

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data):


	Three months ended March 31,
	2021		2020
Net income	$	23,731	$	16,834
Weighted-average number of common shares outstanding (for basic calculation)	21,149		20,780
Dilutive securities	546		727
Weighted-average common and common equivalent shares outstanding (for diluted calculation)	21,695		21,507
EPS — basic	$	1.12	$	0.81
EPS — diluted	$	1.09	$	0.78

Derivative Financial Instruments (Notes)

3 Months Ended

Mar. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

Derivatives and Hedging Activities

Hedge Accounting and Hedging Program

The purpose of our hedging program is to manage the foreign currency exchange rate risk on forecasted expenses denominated in currencies other than the functional currency of the operating unit. We do not issue derivatives for trading or speculative purposes.

To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The par forward contract is designated and qualifies as a cash flow hedge. Our derivative instruments are recorded at fair value on the condensed consolidated balance sheets and are classified based on the instrument's maturity date. We record changes in the intrinsic value of the effective portion of the gain or loss on the derivative instrument as a component of Other Comprehensive Income and we reclassify that gain or loss into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.

In March 2020, we entered into a one-year cross-currency par forward contract that extends our current hedge of a portion of our Mexico forecasted expenses denominated in Pesos ("MXN"). The total notional amount of this outstanding derivative as of March 31, 2021 was approximately 327.6 million MXN. The term of the one-year contract is November 3, 2020 to December 1, 2021. The derivative instrument matures in equal monthly amounts at a fixed forward rate of 24.26 MXN/USD.

In November 2018, we entered into a one-year cross-currency par forward contract that hedges of a portion of our Mexico forecasted expenses denominated in MXN. The term of the one-year hedge was November 1, 2019 to November 3, 2020. The derivative instrument matured in equal monthly amounts at a fixed forward rate of 22.109 MXN/USD.

The following table presents the fair values of our derivative instruments included within the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 (in thousands):


	Derivatives
	Condensed Consolidated Balance Sheet Location	March 31, 2021		December 31, 2020
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:
	Prepaid expenses and other current assets	$	2,312	$	3,555



Total derivatives designated as cash flow hedging instruments		$	2,312	$	3,555

The following table presents the amounts affecting the Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020 (in thousands):


	Line Item in the Condensed Consolidated Statements of Operations	Three months ended March 31,
		2021		2020
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	841	$	692

We recognized the following (losses) gains on our foreign exchange contracts designated as a cash flow hedge (in thousands):


	Amount of Loss Recognized in Other Comprehensive Income on Derivatives				Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Three months ended March 31,					Three months ended March 31,

	2021		2020		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2021		2020
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	(402)	$	(3,192)	Cost of goods sold	$	841	$	692
Total derivatives designated as cash flow hedging instruments	$	(402)	$	(3,192)		$	841	$	692

As of March 31, 2021, we expect approximately $2.3 million of the deferred gains on the outstanding derivatives in accumulated other comprehensive income to be reclassified to net income during the next twelve months concurrent with the underlying hedged transactions also being reported in net income.

Fair Value Measures and Disclosures (Notes)

3 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Disclosures

Fair Value Measurement

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. There are three levels of inputs that may be used to measure fair value:

•Level 1: quoted prices in active markets for identical assets or liabilities;

•Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or

•Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair values of the assets or liabilities.

Earn-out Liability

In 2017, we recognized an earn-out liability upon the acquisition of HIS from Pfizer. Pfizer was entitled to receive between $191.3 million and $225.0 million in additional cash consideration based on the achievement of certain performance targets for the combined company for the three years ending December 31, 2019. The initial fair value of the earn-out was determined by employing a Monte Carlo simulation in a risk neutral framework. The underlying simulated variable was adjusted EBITDA. The adjusted EBITDA volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model included other assumptions including the market price of risk, which was calculated as the weighted average cost of capital ("WACC") less the long term risk free rate. The initial value assigned to the contingent consideration was a result of forecasted product demand of our HIS business. At each reporting date subsequent to the acquisition we remeasured the earn-out using the same methodology above and recognized any changes in value. As of December 31, 2019, we determined that we did not meet the necessary performance targets that would require payout of any of the HIS earn-out liability. As of the date of this filing, Pfizer has disputed our determination that the performance targets requiring payout of the HIS earn-out liability were not met. The dispute is being resolved by binding arbitration that will likely be concluded during the third quarter of 2021. Given the uncertainty of any arbitration, it may be possible that we will incur a loss with regards to this matter. If we are unsuccessful in arbitration such that it is determined that we met the necessary performance targets for any of the HIS earn-out liability, we will be obligated to pay Pfizer between $191.3 million and $225.0 million in additional cash consideration.

In the fourth quarter of 2019, we recognized an earn-out liability related to the acquisition of Pursuit Vascular, Inc. ("Pursuit"). Pursuit's former equity holders are entitled up to $50.0 million in additional cash consideration contingent upon the achievement of certain sales and gross profit targets for specific customers. The earn-out will be calculated as a percentage of gross profit achieved during the earn-out period against a pre-determined target gross profit, not to exceed $50.0 million. We used a Monte Carlo simulation model to determine the fair value of the earn-out liability. The Monte Carlo simulation model utilizes multiple input variables to determine the value of the earn-out liability including historical volatility, a risk free interest rate, counter party credit risk and projected future gross profit, see below simulation input table related to Pursuit. The historical volatility was based on the median of ICU and a certain peer group. The risk-free interest rate is equal to the yield, as of the valuation date, of the zero-coupon U.S. Treasury bill that is commensurate with the term of the earn-out. The counter party credit risk is based on a synthetic credit rating of B1. If the probabilities in the model significantly change from what we initially and subsequently anticipate, the change could have a significant impact on our financial statements in the period recognized. Our contingent earn-out liability is separately stated in our condensed consolidated balance sheets.

The following tables provide a reconciliation of the Level 3 earn-out liabilities measured at estimated fair value (in thousands):


	Pursuit
	Earn-out Liability
Accrued balance, January 1, 2021	$	26,300

Change in fair value of earn-out (included in income from operations as a separate line item)	—
Accrued balance, March 31, 2021	$	26,300


	Pursuit
	Earn-out Liability
Accrued balance, January 1, 2020	$	17,300

Change in fair value of earn-out (included in income from operations as a separate line item)	—
Accrued balance, March 31, 2020	$	17,300

The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities:

Pursuit Earn-out


Simulation Input	As of March 31, 2021		As of December 31, 2020		As of March 31, 2020
Revenue/Gross Profit Volatility	25.00	%	25.00	%	20.00	%
Discount Rate	12.50	%	12.50	%	15.00	%
Risk Free Rate	0.09	%	0.09	%	1.55	%
Counter Party Risk	3.10	%	3.10	%	6.00	%

Investments and Foreign Currency Contracts

The fair value of our investments is estimated using observable market-based inputs such as quoted prices, interest rates and yield curves or Level 2 inputs, which consisted of corporate bonds.

The fair value of our Level 2 forward currency contracts are estimated using observable market inputs such as known notional value amounts, spot and forward exchange rates. These inputs relate to liquid, heavily traded currencies with active markets which are available for the full term of the derivative.

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):


	Fair value measurements at March 31, 2021
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	11,693	$	—	$	11,693	$	—
Long-term	18,834		—		18,834		—
Foreign exchange forwards:
Prepaid expenses and other current assets	2,312		—		2,312		—

Total Assets	$	32,839	$	—	$	32,839	$	—

Liabilities:
Earn-out liability	$	26,300	$	—	$	—	$	26,300



Total Liabilities	$	26,300	$	—	$	—	$	26,300


	Fair value measurements at December 31, 2020
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	14,687	$	—	$	14,687	$	—
Long-term	12,974		—		12,974		—
Foreign exchange forwards:
Prepaid expenses and other current assets	3,555		—		3,555		—

Total Assets	$	31,216	$	—	$	31,216	$	—

Liabilities:
Earn-out liability	$	26,300	$	—	$	—	$	26,300



Total Liabilities	$	26,300	$	—	$	—	$	26,300

Investments, Debt and Equity Securities [Abstract]

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Investment Securities (Notes)

3 Months Ended

Mar. 31, 2021

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Investment Securities

Our investment securities currently consist of short-term and long-term corporate bonds. Our investment securities are considered available-for-sale and are “investment grade” and carried at fair value. Available-for-sale securities are recorded at fair value, and unrealized holding gains and losses are recorded, net of tax, as a component of accumulated other comprehensive income. Unrealized losses on available-for-sale securities are charged against net earnings when a decline in fair value is determined to be other than temporary. Our management reviews several factors to determine whether a loss is other than temporary, such as the length and extent of the fair value decline, the financial condition and near term prospects of the issuer, and for equity investments, our intent and ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. The amortized cost of the debt securities are adjusted for the amortization of premiums computed under the effective interest method. Such amortization is included in investment income in other income (expense), net on our condensed consolidated statements of operations. There have been no realized gains or losses on their disposal. Realized gains and losses are accounted for on the specific identification method. The scheduled maturities of the debt securities are between 2021 and 2024. All short-term investment securities are callable within one year.

Our short investment securities consisted of the following (in thousands):


	As of March 31, 2021
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	11,693	$	—	$	11,693
Long-term corporate bonds	18,834		—		18,834
Total investment securities	$	30,527	$	—	$	30,527

	As of December 31, 2020
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	14,687	$	—	$	14,687
Long-term corporate bonds	12,974		—		12,974
Total investment securities	$	27,661	$	—	$	27,661

Prepaids and Other Current Assets (Notes)

3 Months Ended

Mar. 31, 2021

Prepaid Expense and Other Assets, Current [Abstract]

Other Current Assets [Text Block]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	March 31, 2021		December 31, 2020
Other prepaid expenses and receivables	$	16,084	$	14,964
Deferred costs	6,554		6,402
Prepaid insurance and property taxes	4,639		6,178
VAT/GST receivable	3,674		3,676
Deferred tax charge	3,856		3,542
Foreign exchange forward contract	2,312		3,555
Deposits	1,343		1,353
Other	1,847		1,822
	$	40,309	$	41,492

Inventories:

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Inventories [Text Block]

Inventories

Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method. Inventory costs consist of those costs directly attributable to products prior to sale including among other things raw material, labor and overhead. Inventories consisted of the following (in thousands):


	March 31, 2021		December 31, 2020
Raw materials	$	122,703	$	126,499
Work in process	39,713		33,053
Finished goods	137,670		155,376
Total inventories	$	300,086	$	314,928

Property and Equipment:

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment [Text Block]

Property and Equipment

Property and equipment consisted of the following (in thousands):


	March 31, 2021		December 31, 2020
Machinery and equipment	$	293,653	$	291,331
Land, building and building improvements	241,608		241,199
Molds	60,381		60,381
Computer equipment and software	98,780		98,311
Furniture and fixtures	7,712		7,767
Instruments placed with customers(1)	91,909		90,383
Construction in progress	55,757		53,724
Total property and equipment, cost	849,800		843,096
Accumulated depreciation	(390,728)		(376,468)
Property and equipment, net	$	459,072	$	466,628

______________________________

(1) Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.

Depreciation expense was $16.3 million and $15.2 million for the three months ended March 31, 2021 and 2020, respectively.

Goodwill and Intangible Assets (Notes)

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

Goodwill and Intangible Assets, Net

Goodwill

The following table presents the changes in the carrying amount of our goodwill (in thousands):


	Total
Balance as of January 1, 2021	$	33,001


Currency translation	(49)
Balance as of March 31, 2021	$	32,952

Intangible Assets, Net

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):


	Weighted Average	March 31, 2021
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	25,423	$	15,466	$	9,957
Customer contracts	12	10,310		5,929		4,381
Non-contractual customer relationships	9	57,748		28,233		29,515
Trademarks	4	425		425		—
Trade name	15	18,268		3,808		14,460
Developed technology	13	152,893		40,062		112,831
Non-compete	3	2,500		1,181		1,319
Total amortized intangible assets		$	267,567	$	95,104	$	172,463

Internally developed software*		$	20,611			$	20,611

Total intangible assets		$	288,178	$	95,104	$	193,074

______________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.


	Weighted Average	December 31, 2020
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	24,797	$	15,056	$	9,741
Customer contracts	12	10,365		5,852		4,513
Non-contractual customer relationships	9	58,061		26,711		31,350
Trademarks	4	425		425		—
Trade name	15	18,270		3,500		14,770
Developed technology	13	152,893		36,927		115,966
Non-compete	3	2,500		972		1,528
Total amortized intangible assets		$	267,311	$	89,443	$	177,868

Internally developed software*		$	19,363			$	19,363

Total intangible assets		$	286,674	$	89,443	$	197,231

______________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.

Intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives. During the three months ended March 31, 2021 and 2020, respectively, intangible asset amortization expense was $5.8 million and $5.8 million, respectively.

As of March 31, 2021 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):


Remainder of 2021	$	17,807
2022	22,806
2023	21,783
2024	21,694
2025	15,980
2026	15,116
Thereafter	57,277
Total	$	172,463

Accrued Liabilities (Notes)

3 Months Ended

Mar. 31, 2021

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities and Other Long-Term Liabilities

Accrued liabilities consist of the following (in thousands):


	March 31, 2021		December 31, 2020
Salaries and benefits	$	26,118	$	25,786
Incentive compensation	8,130		27,023

Operating lease liability-ST	8,872		8,740



Accrued sales taxes	2,435		2,146
Restructuring accrual	3,058		3,421

Deferred revenue	8,195		5,566
Accrued other taxes	923		3,540
Accrued professional fees	730		1,273
Legal accrual	1,291		900

Distribution fees	5,080		5,300
Warranties and returns	554		1,027
Accrued freight	7,715		6,784




Other	5,955		5,515
	$	79,056	$	97,021

Other long-term liabilities consist of the following (in thousands):


	March 31, 2021		December 31, 2020


Operating lease liability-LT	$	39,588	$	41,019
Benefits	1,180		1,183
Accrued rent	1,427		1,462
Contract liabilities-LT	303		337

Financing lease liability-LT	2,330		2,388
Deferred revenue	693		864
Other	589		582
	$	46,110	$	47,835

Income Taxes:	3 Months Ended
Income Taxes:	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes Income taxes were accrued at an estimated effective tax rate of 12% and 17% for the three months ended March 31, 2021 and 2020, respectively. The effective tax rate for the three months ended March 31, 2021 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, global intangible low-taxed income ("GILTI"), foreign-derived intangible income ("FDII") and tax credits. The effective tax rate during the three months ended March 31, 2021 included a discrete tax benefit of $1.8 million related to excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period. The effective tax rate for the three months ended March 31, 2020 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, GILTI, FDII and tax credits.

Stockholders' Equity Note Disclosure

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Long-Term Obligations (Notes)	3 Months Ended
Long-Term Obligations (Notes)	Mar. 31, 2021
LOng-Term Obligations Disclosure [Abstract]
Long-term Debt [Text Block]	Long-Term Obligations Five-year Senior Secured Revolving Credit Facility ("Credit Facility") On November 8, 2017, we entered into a Credit Facility with various lenders for $150.0 million, with Wells Fargo Bank, N.A. as the administrative agent, swingline lender and issuing lender. During March 2020, as a result of market uncertainty caused by COVID-19, we preemptively borrowed $150.0 million on our Credit Facility as a conservative measure to manage any potential short-term liquidity risk. In September 2020, we fully repaid the borrowings under our Credit Facility. As of March 31, 2021, we had no borrowings and $150.0 million of availability under the Credit Facility. Principal payments on the revolving Credit Facility are made at our discretion with the unpaid amount due at maturity. The Credit Facility matures on November 8, 2022. Interest on borrowings under the Credit Facility, at our option, is based on the Base Rate plus applicable margin or the London Interbank Offered Rate ("LIBOR") plus applicable margin, see further details in Part II, Item 8, of our 2019 Annual Report on Form 10-K. Debt Covenants The Credit Facility contains certain financial covenants pertaining to Consolidated Fixed Charge Coverage and Consolidated Total Leverage Ratios. In addition, the Credit Facility has restrictions pertaining to limitations on debt, liens, negative pledges, loans, advances, acquisitions, other investments, dividends, distributions, redemptions, repurchases of equity interests, fundamental changes and asset sales and other dispositions, prepayments, redemptions and purchases of subordinated debt and other junior debt, transactions with affiliates, dividend and payment restrictions affecting subsidiaries, changes in line of business, fiscal year and accounting practices and amendment of organizational documents and junior debt documents. The Consolidated Leverage Ratio is defined as the ratio of Consolidated Total Funded Indebtedness on such date, to Consolidated Adjusted EBITDA, as defined under the Credit Facility Agreement, for the most recently completed four fiscal quarters. The maximum Consolidated Leverage Ratio is not more than 3.00 to 1.00. The Consolidated Fixed Charge Coverage Ratio is defined as the ratio of: (a) Consolidated Adjusted EBITDA less the sum of (i) capital expenditures, (ii) federal, state, local and foreign income taxes paid in cash and (iii) cash restricted payments made after the closing date, to (b) Consolidated Fixed Charges for the most recently completed four fiscal quarters, calculated on a pro forma basis. The minimum Consolidated Fixed Charge Coverage Ratio is 2.00 to 1.00. We were in compliance with all financial covenants as of March 31, 2021.

Commitments and Contingencies:	3 Months Ended
Commitments and Contingencies:	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies [Text Block]	Commitments and Contingencies Legal Proceedings From time to time, we are involved in various legal proceedings, most of which are routine litigation, in the normal course of business. Our management does not believe that the resolution of the unsettled legal proceedings that we are involved with will have a material adverse impact on our financial position or results of operations. Off-Balance Sheet Arrangements In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters or other matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification. Contingencies During November 2019, we acquired Pursuit. Total consideration for the acquisition includes a potential contractual earn-out of up to $50.0 million, to be paid to former Pursuit equity holders, calculated based upon the achievement of certain performance targets during the earn-out period (see Note 8: Fair Value Measurement). We had a contractual obligation in connection with our 2017 acquisition of HIS, which as of December 31, 2019 we determined did not meet the necessary performance targets that would require payout of any of the HIS earn-out liability. As of the date of this filing, Pfizer has disputed our determination that the performance targets requiring payout of the HIS earn-out liability were not met. The dispute is being resolved by binding arbitration that will likely be concluded during the third quarter of 2021. Given the uncertainty of any arbitration, it may be possible that we will incur a loss with regards to this matter. If we are unsuccessful in arbitration such that it is determined that we met the necessary performance targets for any of the HIS earn- out liability, we will have to pay between $191.3 million and $225.0 million in additional cash consideration (see Note 8, Fair Value Measurements). Commitments We have non-cancellable operating lease agreements where we are contractually obligated to pay certain lease payment amounts (see Note 5: Leases).

Collaborative and Other Arrangements (Notes)	3 Months Ended
Collaborative and Other Arrangements (Notes)	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaborative Arrangement Disclosure [Text Block]	Collaborative and Other Arrangements On February 3, 2017, we entered into two Manufacturing and Supply Agreements ("MSAs"), (i) whereby Pfizer will manufacture and supply us with certain agreed upon products for an initial five-year term with a one-time two-year option to extend and (ii) whereby we will manufacture and supply Pfizer certain agreed upon products for a term of five or ten years depending on the product, also with a one-time two-year option to extend. The MSAs provide each party with mutually beneficial interests and both of the MSAs are to be jointly managed by both Pfizer and ICU. The initial supply price, which will be annually updated, is in full consideration for all costs associated with the manufacture, documentation, packaging and certification of the products. On January 1, 2021, we amended our MSA with Pfizer, whereby we manufacture and supply certain agreed upon products to Pfizer. The amendments included a change to the term of the agreement to end on December 31, 2024 with Pfizer's unilateral election to extend through December 31, 2025. Other changes to the terms of the MSA included (i) amendments to our level of supply of products to Pfizer, (ii) certain changes to our manufacturing lines, (iii) updates to our supply price with added volume price tiers for annual periods and (iv) certain minimum purchase requirements for certain products.

Equity

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Stockholders' Equity

Treasury Stock

In August 2019, our Board of Directors approved a new share purchase plan to purchase up to $100.0 million of our common stock. This plan replaced our existing plan and has no expiration date. During the three months ended March 31, 2021, we did not purchase any shares of our common stock under our stock purchase plans. As of March 31, 2021, all of the $100.0 million available for purchase was remaining under the plan. We are currently limited on share purchases in accordance with the terms and conditions of our Credit Facility (see Note 16: Long-Term Obligations).

For the three months ended March 31, 2021, we withheld 37,423 shares of our common stock from employee vested restricted stock units in consideration for $7.7 million in payments made on the employee's behalf for their minimum statutory income tax withholding obligations. For the three months ended March 31, 2020, we withheld 63,511 shares of our common stock from employee vested restricted stock units in consideration for $12.2 million in payments made on the employee's behalf for their minimum statutory income tax withholding obligations. Treasury stock is used to issue shares for stock option exercises, restricted stock grants and employee stock purchase plan stock purchases.

Accumulated Other Comprehensive (Loss) Income

The components of accumulated other comprehensive (loss) income ("AOCI"), net of tax, were as follows (in thousands):


	Foreign Currency Translation Adjustments		Unrealized Gains on Cash Flow Hedges		Other Adjustments		Total
Balance as of January 1, 2021	$	(4,381)	$	2,784	$	75	$	(1,522)
Other comprehensive (loss) income before reclassifications	(7,458)		(306)		12		(7,752)
Amounts reclassified from AOCI	—		(639)		—		(639)
Other comprehensive (loss) income	(7,458)		(945)		12		(8,391)
Balance as of March 31, 2021	$	(11,839)	$	1,839	$	87	$	(9,913)


	Foreign Currency Translation Adjustments		Unrealized Gains on Cash Flow Hedges		Other Adjustments		Total
Balance as of January 1, 2020	$	(17,310)	$	1,880	$	28	$	(15,402)
Other comprehensive loss before reclassifications	(10,477)		(2,426)		(81)		(12,984)
Amounts reclassified from AOCI	—		(526)		—		(526)
Other comprehensive loss	(10,477)		(2,952)		(81)		(13,510)
Balance as of March 31, 2020	$	(27,787)	$	(1,072)	$	(53)	$	(28,912)

Restructuring, Strategic Transaction and Integration (Tables)

3 Months Ended

Mar. 31, 2021

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]

The following table summarizes the details of changes in our restructuring-related accrual for the period ended March 31, 2021 (in thousands):


	Accrued Balance January 1, 2021		Charges Incurred		Payments		Currency Translation		Accrued Balance March 31, 2021
Severance pay and benefits	$	1,858	$	43	$	(435)	$	12	$	1,478

Facility closure expenses	1,563		—		—		17		1,580
	$	3,421	$	43	$	(435)	$	29	$	3,058

Revenue (Tables)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table represents our revenues disaggregated by geography (in thousands):


	For the three months ended March 31,
Geography	2021		2020
Europe, the Middle East and Africa	$	34,800	$	37,928



Other Foreign	55,895		60,521
Total Foreign	90,695		98,449
United States	227,351		230,158
Total Revenues	$	318,046	$	328,607

The following table represents our revenues disaggregated by product (in thousands):


	For the three months ended March 31,
Product line	2021		2020
Infusion Consumables	$	126,370	$	123,507
Infusion Systems	84,334		88,380
IV Solutions	94,176		104,291
Critical Care	13,166		12,429

Total Revenues	$	318,046	$	328,607

Contract with Customer, Asset and Liability [Table Text Block]

The following table presents our changes in the contract balances for the three months ended March 31, 2021 and 2020 (in thousands):


	Contract Liabilities
Beginning balance, January 1, 2021	$	(6,430)
Equipment revenue recognized	461
Equipment revenue deferred due to implementation	(2,921)
Software revenue recognized	1,796
Software revenue deferred due to implementation	(1,794)
Ending balance, March 31, 2021	$	(8,888)

Beginning balance, January 1, 2020	$	(4,855)
Equipment revenue recognized	1,802
Equipment revenue deferred due to implementation	(3,990)
Software revenue recognized	1,235
Software revenue deferred due to implementation	(2,664)
Ending balance, March 31, 2020	$	(8,472)

Leases (Tables)

3 Months Ended

Mar. 31, 2021

Leases [Abstract]

Lease, Cost [Table Text Block]

The following table presents the components of our lease cost (in thousands):


	For the three months ended March 31
	2021		2020
Operating lease cost	$	2,835	$	2,791

Finance lease cost - interest	31		29

Finance lease cost - amortization of ROU asset	151		—

Short-term lease cost	3		54



Total lease cost	$	3,020	$	2,874

Cash Flow, Supplemental Disclosures [Text Block]

The following table presents the supplemental cash flow information related to our leases (in thousands):


	For the three months ended March 31,
	2021		2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	2,821	$	2,457
Operating cash flows from finance leases	$	31	$	29

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	1,095	$	19,094
Finance leases	$	184	$	800

Assets and Liabilities, Leases [Table Text Block]

The following table presents the supplemental balance sheet information related to our operating leases (in thousands, except lease term and discount rate):


	As of March 31, 2021			As of December 31, 2020
Operating leases
Operating lease right-of-use assets	$	45,259		$	46,571

Accrued liabilities	$	8,872		$	8,740
Other long-term liabilities	39,588			41,019
Total operating lease liabilities	$	48,460		$	49,759

Weighted Average Remaining Lease Term
Operating leases	6.5 years			6.7 years

Weighted Average Discount Rate
Operating leases	5.00		%	5.02		%

The following table presents the supplemental balance sheet information related to our finance leases (in thousands, except lease term and discount rate):


	As of March 31, 2021			As of December 31, 2020
Financing leases
Financing lease right-of-use assets	$	2,877		$	2,915

Accrued liabilities	$	583		$	554
Other long-term liabilities	2,330			2,388
Total financing lease liabilities	$	2,913		$	2,942

Weighted Average Remaining Lease Term
Financing leases	6.2 years			6.4 years

Weighted Average Discount Rate
Financing leases	4.27		%	4.27		%

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

As of March 31, 2021, the maturities of our operating and financing lease liabilities for each of the next five years is approximately (in thousands):


	Operating Leases		Finance Leases
Remainder of 2021	$	8,352	$	520
2022	10,316		693
2023	9,120		693
2024	8,317		379
2025	5,008		211
2026	4,733		189
Thereafter	10,602		614
Total Lease Payments	56,448		3,299
Less imputed interest	(7,988)		(386)
Total	$	48,460	$	2,913

Net Income Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table presents the calculation of net earnings per common share (“EPS”) — basic and diluted (in thousands, except per share data):


	Three months ended March 31,
	2021		2020
Net income	$	23,731	$	16,834
Weighted-average number of common shares outstanding (for basic calculation)	21,149		20,780
Dilutive securities	546		727
Weighted-average common and common equivalent shares outstanding (for diluted calculation)	21,695		21,507
EPS — basic	$	1.12	$	0.81
EPS — diluted	$	1.09	$	0.78

Derivative Financial Instruments (Tables)

3 Months Ended

Mar. 31, 2021

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]

The following table presents the fair values of our derivative instruments included within the Condensed Consolidated Balance Sheets as of March 31, 2021 and December 31, 2020 (in thousands):


	Derivatives
	Condensed Consolidated Balance Sheet Location	March 31, 2021		December 31, 2020
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contract:
	Prepaid expenses and other current assets	$	2,312	$	3,555



Total derivatives designated as cash flow hedging instruments		$	2,312	$	3,555

The following table presents the amounts affecting the Condensed Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020 (in thousands):


	Line Item in the Condensed Consolidated Statements of Operations	Three months ended March 31,
		2021		2020
Derivatives designated as cash flow hedging instruments
Foreign exchange forward contracts	Cost of goods sold	$	841	$	692

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]

We recognized the following (losses) gains on our foreign exchange contracts designated as a cash flow hedge (in thousands):


	Amount of Loss Recognized in Other Comprehensive Income on Derivatives				Amount of Gain Reclassified From Accumulated Other Comprehensive Income into Income
	Three months ended March 31,					Three months ended March 31,

	2021		2020		Location of Gain Reclassified From Accumulated Other Comprehensive Income into Income	2021		2020
Derivatives designated as cash flow hedges:
Foreign exchange forward contract	$	(402)	$	(3,192)	Cost of goods sold	$	841	$	692
Total derivatives designated as cash flow hedging instruments	$	(402)	$	(3,192)		$	841	$	692

Fair Value Measures and Disclosures (Tables)

3 Months Ended

Mar. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The following tables provide a reconciliation of the Level 3 earn-out liabilities measured at estimated fair value (in thousands):


	Pursuit
	Earn-out Liability
Accrued balance, January 1, 2021	$	26,300

Change in fair value of earn-out (included in income from operations as a separate line item)	—
Accrued balance, March 31, 2021	$	26,300


	Pursuit
	Earn-out Liability
Accrued balance, January 1, 2020	$	17,300

Change in fair value of earn-out (included in income from operations as a separate line item)	—
Accrued balance, March 31, 2020	$	17,300

Fair Value Measurement Inputs and Valuation Techniques

The following tables provide quantitative information about Level 3 inputs for fair value measurement of our earn-out liabilities:Pursuit Earn-out


Simulation Input	As of March 31, 2021		As of December 31, 2020		As of March 31, 2020
Revenue/Gross Profit Volatility	25.00	%	25.00	%	20.00	%
Discount Rate	12.50	%	12.50	%	15.00	%
Risk Free Rate	0.09	%	0.09	%	1.55	%
Counter Party Risk	3.10	%	3.10	%	6.00	%

Fair Value, by Balance Sheet Grouping

Our assets and liabilities measured at fair value on a recurring basis consisted of the following (Level 1, 2 and 3 inputs as defined above) (in thousands):


	Fair value measurements at March 31, 2021
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	11,693	$	—	$	11,693	$	—
Long-term	18,834		—		18,834		—
Foreign exchange forwards:
Prepaid expenses and other current assets	2,312		—		2,312		—

Total Assets	$	32,839	$	—	$	32,839	$	—

Liabilities:
Earn-out liability	$	26,300	$	—	$	—	$	26,300



Total Liabilities	$	26,300	$	—	$	—	$	26,300


	Fair value measurements at December 31, 2020
	Total carrying value		Quoted prices in active markets for identical assets (level 1)		Significant other observable inputs (level 2)		Significant unobservable inputs (level 3)
Assets:
Available for sale securities:
Short-term	$	14,687	$	—	$	14,687	$	—
Long-term	12,974		—		12,974		—
Foreign exchange forwards:
Prepaid expenses and other current assets	3,555		—		3,555		—

Total Assets	$	31,216	$	—	$	31,216	$	—

Liabilities:
Earn-out liability	$	26,300	$	—	$	—	$	26,300



Total Liabilities	$	26,300	$	—	$	—	$	26,300

Investment Securities (Tables)

3 Months Ended

Mar. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities [Table Text Block]

Our short investment securities consisted of the following (in thousands):


	As of March 31, 2021
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	11,693	$	—	$	11,693
Long-term corporate bonds	18,834		—		18,834
Total investment securities	$	30,527	$	—	$	30,527

	As of December 31, 2020
	Amortized Cost		Unrealized Holding Gains (Losses)		Fair Value
Short-term corporate bonds	$	14,687	$	—	$	14,687
Long-term corporate bonds	12,974		—		12,974
Total investment securities	$	27,661	$	—	$	27,661

Prepaids and Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2021

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

Prepaid expenses and other current assets consist of the following (in thousands):


	March 31, 2021		December 31, 2020
Other prepaid expenses and receivables	$	16,084	$	14,964
Deferred costs	6,554		6,402
Prepaid insurance and property taxes	4,639		6,178
VAT/GST receivable	3,674		3,676
Deferred tax charge	3,856		3,542
Foreign exchange forward contract	2,312		3,555
Deposits	1,343		1,353
Other	1,847		1,822
	$	40,309	$	41,492

Inventories (Tables)

3 Months Ended

Mar. 31, 2021

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consisted of the following (in thousands):


	March 31, 2021		December 31, 2020
Raw materials	$	122,703	$	126,499
Work in process	39,713		33,053
Finished goods	137,670		155,376
Total inventories	$	300,086	$	314,928

Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2021

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consisted of the following (in thousands):


	March 31, 2021		December 31, 2020
Machinery and equipment	$	293,653	$	291,331
Land, building and building improvements	241,608		241,199
Molds	60,381		60,381
Computer equipment and software	98,780		98,311
Furniture and fixtures	7,712		7,767
Instruments placed with customers(1)	91,909		90,383
Construction in progress	55,757		53,724
Total property and equipment, cost	849,800		843,096
Accumulated depreciation	(390,728)		(376,468)
Property and equipment, net	$	459,072	$	466,628

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill [Table Text Block]

The following table presents the changes in the carrying amount of our goodwill (in thousands):


	Total
Balance as of January 1, 2021	$	33,001


Currency translation	(49)
Balance as of March 31, 2021	$	32,952

Schedule of Intangible Assets and Goodwill [Table Text Block]

Intangible assets, carried at cost less accumulated amortization and amortized on a straight-lined basis, were as follows (in thousands):


	Weighted Average	March 31, 2021
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	25,423	$	15,466	$	9,957
Customer contracts	12	10,310		5,929		4,381
Non-contractual customer relationships	9	57,748		28,233		29,515
Trademarks	4	425		425		—
Trade name	15	18,268		3,808		14,460
Developed technology	13	152,893		40,062		112,831
Non-compete	3	2,500		1,181		1,319
Total amortized intangible assets		$	267,567	$	95,104	$	172,463

Internally developed software*		$	20,611			$	20,611

Total intangible assets		$	288,178	$	95,104	$	193,074

______________________________

* Internally developed software will be amortized when the projects are complete and the assets are ready for their intended use.


	Weighted Average	December 31, 2020
	Amortization Life in Years	Cost		Accumulated Amortization		Net
Patents	10	$	24,797	$	15,056	$	9,741
Customer contracts	12	10,365		5,852		4,513
Non-contractual customer relationships	9	58,061		26,711		31,350
Trademarks	4	425		425		—
Trade name	15	18,270		3,500		14,770
Developed technology	13	152,893		36,927		115,966
Non-compete	3	2,500		972		1,528
Total amortized intangible assets		$	267,311	$	89,443	$	177,868

Internally developed software*		$	19,363			$	19,363

Total intangible assets		$	286,674	$	89,443	$	197,231

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

As of March 31, 2021 estimated annual amortization for our intangible assets for each of the next five years is approximately (in thousands):


Remainder of 2021	$	17,807
2022	22,806
2023	21,783
2024	21,694
2025	15,980
2026	15,116
Thereafter	57,277
Total	$	172,463

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2021

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities consist of the following (in thousands):


	March 31, 2021		December 31, 2020
Salaries and benefits	$	26,118	$	25,786
Incentive compensation	8,130		27,023

Operating lease liability-ST	8,872		8,740



Accrued sales taxes	2,435		2,146
Restructuring accrual	3,058		3,421

Deferred revenue	8,195		5,566
Accrued other taxes	923		3,540
Accrued professional fees	730		1,273
Legal accrual	1,291		900

Distribution fees	5,080		5,300
Warranties and returns	554		1,027
Accrued freight	7,715		6,784




Other	5,955		5,515
	$	79,056	$	97,021

Other long-term liabilities consist of the following (in thousands):


	March 31, 2021		December 31, 2020


Operating lease liability-LT	$	39,588	$	41,019
Benefits	1,180		1,183
Accrued rent	1,427		1,462
Contract liabilities-LT	303		337

Financing lease liability-LT	2,330		2,388
Deferred revenue	693		864
Other	589		582
	$	46,110	$	47,835

Equity (Tables)

3 Months Ended

Mar. 31, 2021

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The components of accumulated other comprehensive (loss) income ("AOCI"), net of tax, were as follows (in thousands):


	Foreign Currency Translation Adjustments		Unrealized Gains on Cash Flow Hedges		Other Adjustments		Total
Balance as of January 1, 2021	$	(4,381)	$	2,784	$	75	$	(1,522)
Other comprehensive (loss) income before reclassifications	(7,458)		(306)		12		(7,752)
Amounts reclassified from AOCI	—		(639)		—		(639)
Other comprehensive (loss) income	(7,458)		(945)		12		(8,391)
Balance as of March 31, 2021	$	(11,839)	$	1,839	$	87	$	(9,913)


	Foreign Currency Translation Adjustments		Unrealized Gains on Cash Flow Hedges		Other Adjustments		Total
Balance as of January 1, 2020	$	(17,310)	$	1,880	$	28	$	(15,402)
Other comprehensive loss before reclassifications	(10,477)		(2,426)		(81)		(12,984)
Amounts reclassified from AOCI	—		(526)		—		(526)
Other comprehensive loss	(10,477)		(2,952)		(81)		(13,510)
Balance as of March 31, 2020	$	(27,787)	$	(1,072)	$	(53)	$	(28,912)

Restructuring, Strategic Transaction and Integration Restructuring (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Restructuring, strategic transaction and integration	$ 2,900	$ 12,300
Restructuring Costs	$ 0	$ 7,200

Restructuring, Strategic Transaction and Integration Liability (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 3,421
Restructuring Charges	43
Payments for Restructuring	435
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	(29)
Restructuring Reserve	3,058
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,858
Restructuring Charges	43
Payments for Restructuring	435
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	(12)
Restructuring Reserve	1,478
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	1,563
Restructuring Charges	0
Payments for Restructuring	0
Restructuring Reserve, Foreign Currency Translation Gain (Loss)	(17)
Restructuring Reserve	$ 1,580

Strategic Transaction and Integration (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restructuring and Related Activities [Abstract]
Strategic Transaction and Integration	$ 2.9	$ 5.1

Revenue (Details) $ in Millions	Mar. 31, 2021 USD ($)
Equipment revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 7.3
Software revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 1.5

Revenue Disaggregated Revenue by Geography (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 318,046	$ 328,607
EMEA [Member]
Disaggregation of Revenue [Line Items]
Revenues	34,800	37,928
Other foreign countries [Member]
Disaggregation of Revenue [Line Items]
Revenues	55,895	60,521
Foreign [Member]
Disaggregation of Revenue [Line Items]
Revenues	90,695	98,449
UNITED STATES
Disaggregation of Revenue [Line Items]
Revenues	$ 227,351	$ 230,158

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Revenue Disaggregated Revenue by Product Line (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disaggregation of Revenue [Line Items]
Revenues	$ 318,046	$ 328,607
Infusion Consumables [Member]
Disaggregation of Revenue [Line Items]
Revenues	126,370	123,507
Infusion Systems [Member]
Disaggregation of Revenue [Line Items]
Revenues	84,334	88,380
IV Solutions [Member]
Disaggregation of Revenue [Line Items]
Revenues	94,176	104,291
Critical Care [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 13,166	$ 12,429

Operating Lease, Right-of-Use Asset

Revenue Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Movement in Deferred Revenue [Roll Forward]
Contract with Customer, Liability	$ (6,430)	$ (4,855)
Contract with Customer, Liability	(8,888)	(8,472)
Equipment revenue [Member]
Movement in Deferred Revenue [Roll Forward]
Increase (Decrease) in Deferred Revenue	461	1,802
Deferred Revenue, Additions	(2,921)	(3,990)
Software revenue [Member]
Movement in Deferred Revenue [Roll Forward]
Increase (Decrease) in Deferred Revenue	1,796	1,235
Deferred Revenue, Additions	$ (1,794)	$ (2,664)

Leases Text (Details)	3 Months Ended
Leases Text (Details)	Mar. 31, 2021
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Option to Extend	5 years
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	15 years

Leases (Details) - USD ($) $ in Thousands	3 Months Ended
Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating Lease, Cost	$ 2,835	$ 2,791
Finance Lease, Interest Expense	31	29
Finance Lease, Right-of-Use Asset, Amortization	151	0
Short-term Lease, Cost	3	54
Lease, Cost	$ 3,020	$ 2,874

Leases Cash Flow, Operating Activities, Lessee (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating Lease, Payments	$ 2,821	$ 2,457
Finance Lease, Interest Payment on Liability	31	29
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	1,095	19,094
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	$ 184	$ 800

Leases Assets and Liabilities, Lessee (Details) - USD ($)
$ in Thousands

Mar. 31, 2021

Dec. 31, 2020

Leases [Abstract]

$ 45,259

$ 46,571

^[1]

Operating Lease, Liability, Current

8,872

8,740

Operating Lease, Liability, Noncurrent

39,588

41,019

Operating Lease, Liability

$ 48,460

$ 49,759

Operating Lease, Weighted Average Remaining Lease Term

6 years 6 months

6 years 8 months 12 days

Operating Lease, Weighted Average Discount Rate, Percent

5.00%

5.02%

Finance Lease, Right-of-Use Asset

$ 2,877

$ 2,915

Finance Lease, Liability, Current

583

554

Finance Lease, Liability, Noncurrent

2,330

2,388

Finance Lease, Liability

$ 2,913

$ 2,942

Finance Lease, Weighted Average Remaining Lease Term

6 years 2 months 12 days

6 years 4 months 24 days

Finance Lease, Weighted Average Discount Rate, Percent

4.27%

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Leases Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 8,352
Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months	10,316
Lessee, Operating Lease, Liability, Payments, Due Year Two	9,120
Lessee, Operating Lease, Liability, Payments, Due Year Three	8,317
Lessee, Operating Lease, Liability, Payments, Due Year Four	5,008
Lessee, Operating Lease, Liability, Payments, Due Year Five	4,733
Lessee, Operating Lease, Liability, Payments, Due after Year Five	10,602
Lessee, Operating Lease, Liability, Payments, Due	56,448
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(7,988)
Operating Lease, Liability	48,460	$ 49,759
Finance Lease, Liability, Payments, Remainder of Fiscal Year	520
Finance Lease, Liability, Payments, Due Next Twelve Months	693
Finance Lease, Liability, Payments, Due Year Two	693
Finance Lease, Liability, Payments, Due Year Three	379
Finance Lease, Liability, Payments, Due Year Four	211
Finance Lease, Liability, Payments, Due Year Five	189
Finance Lease, Liability, Payments, Due after Year Five	614
Finance Lease, Liability, Payment, Due	3,299
Finance Lease, Liability, Undiscounted Excess Amount	(386)
Finance Lease, Liability	$ 2,913	$ 2,942

Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,080	15,333
Net Income	$ 23,731	$ 16,834
Weighted average number of common shares outstanding (for basic calculation)	21,149,000	20,780,000
Dilutive securities	546,000	727,000
Diluted (in shares)	21,695,000	21,507,000
EPS - basic	$ 1.12	$ 0.81
Diluted (In dollars per share)	$ 1.09	$ 0.78

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

Net Income Per Share (Details 1) - $ / shares	3 Months Ended
Net Income Per Share (Details 1) - $ / shares	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,080	15,333
Dilutive securities	546,000	727,000
Diluted (in shares)	21,695,000	21,507,000
Basic (in dollars per share)	$ 1.12	$ 0.81
Diluted (in dollars per share)	$ 1.09	$ 0.78

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Derivative Financial Instruments (Details) $ in Millions	Mar. 31, 2021 USD ($)	Mar. 31, 2021 MXN ($)
Derivative [Line Items]
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 2,300,000
Hedge 2 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	24.26	24.26
Derivative Asset, Notional Amount		$ 327.6
Hedge 3 [Member] [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	22.109	22.109

Derivative Financial Instruments Derivative Instruments and Hedging Activities - FV of Derivative Instruments Included Within Consolidated Balance Sheet (Details) - Foreign Exchange Forward [Member] - Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 2,312	$ 3,555
Derivative Financial Instruments, Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset	$ 2,312	$ 3,555

Derivative Financial Instruments Derivative Instruments and Hedging Activities - Amounts Affecting Consolidated Statements of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ 841	$ 692

Derivative Financial Instruments Derivative Instruments and Hedging Activities - Cash Flow Hedge Activity Included in Accumulated Other Comprehensive Income (Loss) (Details) - Cost of Sales [Member] - Foreign Exchange Forward [Member] - Cash Flow Hedging [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion	$ (402)	$ (3,192)
Derivative Instruments, Gain Reclassified from Accumulated OCI into Income, Effective Portion	$ 841	$ 692

Fair Value Measures and Disclosures (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Hospira [Member] \| Maximum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
contingent consideration gross		$ 225.0
Hospira [Member] \| Minimum [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
contingent consideration gross		$ 191.3
Pursuit Vascular, Inc. [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
contingent consideration gross	$ 50.0

Fair Value Measures and Disclosures Liabilities Recurring Basis Unobservable Input Reconciliation Pursuit (Details) - Pursuit Vascular, Inc. [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
CONTINGENT EARN-OUT LIABILITY	$ 26,300	$ 17,300	$ 26,300	$ 17,300
Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)	$ 0	$ 0

Fair Value Measures and Disclosures Liabilities Recurring Basis Unobservable Input Reconciliation Hospira (Details) - Pursuit Vascular, Inc. [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
CONTINGENT EARN-OUT LIABILITY	$ 26,300	$ 17,300	$ 26,300	$ 17,300
Fair Value, Liability, Recurring Basis, Still Held, Unrealized Gain (Loss)	$ 0	$ 0

Fair Value Measures and Disclosures Liability Measurement Inputs (Details) - Pursuit Vascular, Inc. [Member]	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2020
MeasurementinputadjustedEBITDAvolatility [Domain]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.2500	0.2500	0.2000
Measurement Input, Discount Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.1250	0.1250	0.1500
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0009	0.0009	0.0155
Measurement Input, Market Price of Risk [Domain]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.0310	0.0310	0.0600

Fair Value Measures and Disclosures Assets and Liabilities by Balance Sheet Grouping (Details) - USD ($)
$ in Thousands

Mar. 31, 2021

Dec. 31, 2020

$ 11,693

$ 14,687

^[1]

18,834

12,974

Earn-out liability [Member]

32,839

31,216

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Liabilities, Total [Member]

26,300

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Prepaid Expenses and Other Current Assets [Member]

26,300

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

2,312

3,555

Fair Value, Inputs, Level 1 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Inputs, Level 1 [Member] | Earn-out liability [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Inputs, Level 1 [Member] | Liabilities, Total [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Inputs, Level 1 [Member] | Prepaid Expenses and Other Current Assets [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

Fair Value, Inputs, Level 2 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

11,693

14,687

18,834

12,974

Fair Value, Inputs, Level 2 [Member] | Earn-out liability [Member]

32,839

31,216

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Inputs, Level 2 [Member] | Liabilities, Total [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Inputs, Level 2 [Member] | Prepaid Expenses and Other Current Assets [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

2,312

3,555

Fair Value, Inputs, Level 3 [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Inputs, Level 3 [Member] | Earn-out liability [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Inputs, Level 3 [Member] | Liabilities, Total [Member]

26,300

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Fair Value, Inputs, Level 3 [Member] | Prepaid Expenses and Other Current Assets [Member]

26,300

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Foreign Currency Contract, Asset, Fair Value Disclosure

$ 0

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Investment Securities (Details) $ in Millions	3 Months Ended
Investment Securities (Details) $ in Millions	Mar. 31, 2021 USD ($)
Debt Securities, Available-for-sale [Line Items]
Gain (Loss) on Sale of Investments	$ 0

Investment Securities Table (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Current	$ 11,693	$ 14,687
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value	11,693	14,687
Available-for-sale Equity Securities, Amortized Cost Basis	30,527	27,661
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax	0	0
Available-for-sale Securities	30,527	27,661
Available-for-sale Debt Security Current [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0	0
Long-term Investments [Domain]
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis	18,834	12,974
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax	0	0
Available-for-sale Securities	$ 18,834	$ 12,974

Prepaids and Other Current Assets Prepaids and Other Assets (Details) - USD ($)
$ in Thousands

Mar. 31, 2021

Dec. 31, 2020

Prepaid Expense and Other Assets, Current [Abstract]

Other Prepaid Expense, Current

$ 16,084

$ 14,964

Deferred Costs and Other Assets

6,554

6,402

Prepaid insurance and property taxes

4,639

6,178

Prepaid Taxes

3,674

3,676

Deferred tax charge

3,856

3,542

Derivative Asset, Current

2,312

3,555

Deposit Assets

1,343

1,353

Other Assets, Current

1,847

1,822

Prepaid expenses and other current assets

$ 40,309

$ 41,492

^[1]

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Inventories (Details) - USD ($)
$ in Thousands

Mar. 31, 2021

Dec. 31, 2020

Inventory Disclosure [Abstract]

Inventory, Raw Materials, Net of Reserves

$ 122,703

$ 126,499

Inventory, Work in Process, Net of Reserves

39,713

33,053

Inventory, Finished Goods, Net of Reserves

137,670

155,376

Total

$ 300,086

$ 314,928

^[1]

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Property and Equipment (Details) - USD ($)
$ in Thousands

Mar. 31, 2021

Dec. 31, 2020

Net property and equipment

$ 849,800

$ 843,096

Accumulated depreciation

(390,728)

(376,468)

459,072

466,628

^[1]

Machinery and Equipment, Gross

293,653

291,331

Furniture and Fixtures, Gross

7,712

7,767

Construction in Progress, Gross

55,757

53,724

Land, Buildings and Improvements [Member]

241,608

241,199

Molds [Member]

Computer Equipment and Software [Member]

60,381

Instruments Placed with Customers [Member]

98,780

98,311

Goodwill and Intangible Assets Disclosure [Abstract]

$ 91,909

$ 90,383

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Property and Equipment Text (Details) $ in Millions	3 Months Ended
Property and Equipment Text (Details) $ in Millions	Mar. 31, 2021 USD ($)
Property, Plant and Equipment [Abstract]
Depreciation	$ 16.3

Goodwill and Intangible Assets Goodwill Table (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2021

Dec. 31, 2020

^[1]

GOODWILL

$ 32,952

$ 33,001

Goodwill, Foreign Currency Translation Gain (Loss)

$ (49)

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Goodwill and Intangible Assets Intangibles Table (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Mar. 31, 2021

Dec. 31, 2020

Finite-Lived Intangible Assets, Accumulated Amortization

$ 267,567

$ 267,311

95,104

89,443

Indefinite-lived Intangible Assets (Excluding Goodwill)

172,463

177,868

20,611

19,363

Intangible Assets, Gross (Excluding Goodwill)

288,178

286,674

INTANGIBLE ASSETS, net

$ 193,074

$ 197,231

^[1]

Patents [Member]

10 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 25,423

$ 24,797

15,466

15,056

Customer Contracts [Member]

$ 9,957

$ 9,741

12 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 10,310

$ 10,365

5,929

5,852

$ 4,381

$ 4,513

9 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 57,748

$ 58,061

28,233

26,711

$ 29,515

$ 31,350

Trademarks [Member]

4 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 425

425

$ 0

Trade Names [Member]

15 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 18,268

$ 18,270

3,808

3,500

Developed Technology Rights [Member]

$ 14,460

$ 14,770

13 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 152,893

40,062

36,927

Noncompete Agreements [Member]

$ 112,831

$ 115,966

3 years

Finite-Lived Intangible Assets, Accumulated Amortization

$ 2,500

1,181

972

Operating Lease, Liability, Current

$ 1,319

$ 1,528

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Goodwill and Intangible Assets Text (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 5.8	$ 5.8

Goodwill and Intangible Assets 5-Year Amortization (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 17,807
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	22,806
Finite-Lived Intangible Assets, Amortization Expense, Year Two	21,783
Finite-Lived Intangible Assets, Amortization Expense, Year Four	21,694
Finite-Lived Intangible Assets, Amortization Expense, Year Five	15,980
Finite-Lived Intangible Assets, Amortization Expense, Year Five	15,116
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	57,277
Finite-Lived Intangible Assets, Net	$ 172,463	$ 177,868

Accrued Liabilities (Details) - USD ($)
$ in Thousands

Mar. 31, 2021

Dec. 31, 2020

Accrued Liabilities [Abstract]

Salaries and benefits

$ 26,118

$ 25,786

Incentive compensation

8,130

27,023

8,872

8,740

Sales taxes

2,435

2,146

Restructuring accrual

3,058

3,421

UnfavorablecontractliabilityST

8,195

5,566

Accrued other taxes

923

3,540

Accrued Professional Fees

730

1,273

Legal accrual

1,291

900

Distribution Fees

5,080

5,300

Warranties and returns

554

1,027

Accrued freight

7,715

6,784

Other

5,955

5,515

Accrued liabilities

$ 79,056

$ 97,021

^[1]

[1]	December 31, 2020 balances were derived from audited consolidated financial statements.

Accrued Liabilities Long-term liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued Liabilities [Abstract]
Operating Lease, Liability, Noncurrent	$ 39,588	$ 41,019
Accrued Employee Benefits	1,180	1,183
Accrued Rent	1,427	1,462
Liabilities for contracts	303	337
Finance Lease, Liability, Noncurrent	2,330	2,388
Contract with Customer, Liability, Noncurrent	693	864
Other Accrued Liabilities, Noncurrent	589	582
OTHER LONG-TERM LIABILITIES	$ 46,110	$ 47,835

Income Taxes Effective tax rate (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	12.00%	17.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%
Share-based Payment Arrangement, Expense, Tax Benefit	$ 1.8

Long-Term Obligations (Details) - USD ($) $ in Millions	3 Months Ended
Long-Term Obligations (Details) - USD ($) $ in Millions	Mar. 31, 2021	Mar. 31, 2020
LOng-Term Obligations Disclosure [Abstract]
Line of Credit Facility, Maximum Borrowing Capacity	$ 150.0
Line of Credit, Current	0.0	$ 150.0
Line of Credit Facility, Remaining Borrowing Capacity	$ 150.0
Line of Credit Facility, Expiration Date	Nov. 08, 2022